---
schema_version: "secwatch.filing_event.v1"
accession: "0001932393-23-000086"
form_type: "8-K"
ticker: "GEHC"
cik: "0001932393"
company_name: "GE HealthCare Technologies Inc."
filed_at: "2023-04-25T23:59:59+00:00"
generated_at: "2026-06-16T17:00:38.800560+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# GE HealthCare Q1 revenue up 12% organic; adjusted EPS $0.85; reaffirms FY guidance

## Summary
- Revenue $4.7B, +8% reported, +12% organic; strong across all segments: Imaging, Ultrasound, PCS, PDx.
- Net income attributable $372M; adjusted EBIT $664M, margin 14.1% (+30bps); adjusted EPS $0.85 vs $0.96.
- Cash from ops $468M, free cash flow $325M; FY guidance: organic revenue growth 5-7%, adj. EPS $3.60-$3.75.
- Board declares dividend $0.03/share; FY adjusted EBIT margin guided 15.0-15.5%.
- Segment margins: Imaging 7.7% (down), Ultrasound 24.1% (up), PCS 14.0% (up), PDx 27.8% (down).

## SEC filing metadata
- accession: 0001932393-23-000086
- form_type: 8-K
- ticker: GEHC
- cik: 0001932393
- company_name: GE HealthCare Technologies Inc.
- filed_at: 2023-04-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1932393/000193239323000086/0001932393-23-000086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1932393/000193239323000086/gehc-20230425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001932393-23-000086
- JSON: https://secwatch.observer/filing/0001932393-23-000086.json
- Plain text: https://secwatch.observer/filing/0001932393-23-000086.txt

## Key facts
- Earnings Releases
  GE HealthCare Technologies Inc. reported First Quarter 2023 results: revenue $4.7 billion, net income $372 million, EPS $0.41. Guidance reaffirmed.
  - Period: First Quarter 2023
  - Revenue: $4.7 billion
  - Net income: $372 million
  - EPS: $0.41
  - Guidance: reaffirmed
  - Result: reported results
  source text: • Revenues of $4.7 billion increased 8% reported and 12% on an Organic basis* year-over-year. Foreign exchange negatively impacted growth by 4%. Total company book-to-bill, defined as Total orders divided by Total revenues, was 1.01 times for the quarter, given strong revenue growth across all segments, led by Pharmaceutical Diagnostics (PDx) recurring sales. • Net income attributable to GE HealthCare was $372 million versus $389 million for the prior year, and Adjusted EBIT* was $664 million versus $599 million. • Net income margin was 7.9% versus 9.0% for the prior year, down 110 basis points (bp s) primarily impacted by interest expense. Adjusted EBIT margin* was 14.1% versus 13.8%, up 30 bps driven by volume, partially offset by mix. Inflation and planned investments were mostly offset by price and productivity actions. Adjusted EBIT margin* for the first quarter of 2023 grew 150 bps versus our estimated 1Q’22 Standalone Adjusted EBIT margin*. • Earnings per share (EPS) f rom conti
  evidence_url: https://www.sec.gov/Archives/edgar/data/1932393/000193239323000086/0001932393-23-000086-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.